Growth of Atopic Dermatitis Market to be Supported by Launch of New Biologics: 2016 Edition

Growth of Atopic Dermatitis Market to be Supported by Launch of New Biologics: 2016 Edition

Published on : Jul 04, 2016

ALBANY, New York, July 04, 2016: ResearchMoz.us has announced the addition of the “Global Atopic Dermatitis Market Report: 2016 Edition” report to its offering. This study provides an extensive evaluation on the market and encapsulates all its key segments. For the compilation of this study, a number of industry leaders and stakeholders have been interviewed and their insights were taken into account. The key factors fuelling the development of the market, the current news relevant to the market, and the problems encountered by the established players also form a key part of this study.

Part one of the report begins by providing an introduction to the market for atopic dermatitis. This part comprises the causes, symptoms, and factors aggravating this disease. In addition, insights on the major stages of atopic dermatitis, the prevention, and treatment scenario of this disease is also an integral part of this study. Atopic dermatitis (AD), also called as atopic eczema, is a kind of skin disease causing skin inflammation characterized by swollen, itchy, cracked, and red skin. The affected areas may release a clear fluid, which may become thicker over a period of time. This disease majorly starts during childhood but can also occur in adults.

The cause of this skin disease is still not known but some studies suggest that it may be caused due to immune system dysfunction, genetics, and dry skin. No particular biologic is available in the market currently, however, the increasing number of research and development activities by the major companies may result in the introduction of the first biologic by 2017. In addition, a number of other products are also seen in the pipeline in the global atopic dermatitis market. In the next section of the report, the regional analysis of the market for atopic dermatitis has been presented. Geographically, the report segments the market into the U.S., the European Union (EU), and Rest of the World (RoW).

Moving further, the report throws light on the major dynamics impacting the development of the market for atopic dermatitis. The increasing population, the rising healthcare expenditures, and the buildup of pollution globally are fuelling the growth of this market. In addition, the high economic growth experienced worldwide also impacts the market positively. The launch of new biologics is a key opportunity seen within the global atopic dermatitis market. On the other hand, the soaring prices of drugs and a lot of time being taken in the adoption of the treatment drugs may negatively impact the growth of the market. In addition, a number of legal regulations implemented worldwide may also impede the growth of the market in the coming years.

The competitive landscape comes next in the report and highlights the major pipeline biologics for the treatment of atopic dermatitis. The key products in this market are Dupilumab, Nemolizumab, Lebrikizumab, and Tralokinumab. The prime players operating in the market are Sanofi, Roche Holding, and AstraZeneca, among others.